Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029

NCT01938482 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: 0.3% GSK1940029 gel
DRUG: 1% GSK1940029 gel
DRUG: 0.3%/1% vehicle gel only

Sponsor

GlaxoSmithKline